Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry

Molecular and Cellular Proteomics

Volumn 14, Issue 1, 2015, Pages 148-161

  Jensen, Pernille Foged ^a   Larraillet, Vincent ^b   Schlothauer, Tilman ^b   Kettenberger, Hubert ^b   Hilger, Maximiliane ^b   Rand, Kasper D ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; DEUTERIUM; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; HYDROGEN; IMMUNOGLOBULIN G;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DEUTERIUM HYDROGEN EXCHANGE; DEUTERIUM HYDROGEN EXCHANGE MASS SPECTROMETRY; ELECTRON TRANSFER DISSOCIATION; ELECTRON TRANSPORT; MASS SPECTROMETRY; NONHUMAN; PEPTIDE MAPPING; PROTEIN CONFORMATION; PROTEIN GLYCOSYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; STRUCTURAL PROTEOMICS; WILD TYPE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL LINE; CRICETULUS; HEK293 CELL LINE; HUMAN; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; CHO CELLS; CRICETULUS; DEUTERIUM; HEK293 CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; HYDROGEN; IMMUNOGLOBULIN G; MASS SPECTROMETRY; MODELS, MOLECULAR; RECEPTORS, FC;

EID: 84920475389     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M114.042044     Document Type: Article

References (60)

1. Nelson, A. L., Dhimolea, E., and Reichert, J. M. (2010) Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 9, 767-774
2. Jefferis, R. (2012) Isotype and glycoform selection for antibody therapeutics. Arch. Biochem. Biophys. 526, 159-166
3. Nimmerjahn, F., and Ravetch, J. V. (2008) Fcy receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34-47
4. Hogarth, P. M., and Pietersz, G. A. (2012) Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat. Rev. Drug Discov. 11, 311-331
5. Wagner, E., and Frank, M. M. (2010) Therapeutic potential of complement modulation. Nat. Rev. Drug Discov. 9, 43-56
6. Roopenian, D. C., and Akilesh, S. (2007) FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715-725
7. Vaughn, D. E., and Bjorkman, P. J. (1998) Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure 6, 63-73
8. Lobo, E. D., Hansen, R. J., and Balthasar, J. P. (2004) Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93, 2645-2668
9. Burmeister, W. P., Gastinel, L. N., Simister, N. E., Blum, M. L, and Bjorkman, P. J. (1994) Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature 372, 336-343
10. West, A. P., Jr., and Bjorkman, P. J. (2000) Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry 39, 9698-9708
11. Burmeister, W. P., Huber, A. H., and Bjorkman, P. J. (1994) Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 372, 379-383
12. Martin, W. L, West, A. P., Jr., Gan, L, and Bjorkman, P. J. (2001) Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol. Cell 7, 867-877
13. Oganesyan, V., Damschroder, M. M., Cook, K. E., Li, Q., Gao, C., Wu, H., and Dall'acqua, W. F. (2014) Structural insights into neonatal Fc receptor-based recycling mechanisms. J. Biol. Chem. 289, 7812-7824
14. Ghetie, V., Popov, S., Borvak, J., Radu, C., Matesoi, D., Medesan, C., Ober, R. J., and Ward, E. S. (1997) Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat. Biotechnol. 15, 637-640
15. Dall'Acqua, W. F., Woods, R. M., Ward, E. S., Palaszynski, S. R., Patel, N. K., Brewah, Y. A., Wu, H., Kiener, P. A., and Langermann, S. (2002) Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J. Immunol. 169, 5171-5180
16. Dall'Acqua, W. F., Kiener, P. A., and Wu, H. (2006) Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 281, 23514-23524
17. Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W. L., Sproule, T. J., Lazar, G. A., Roopenian, D. C., and Desjarlais, J. R. (2010) Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28, 157-159
18. Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T, Keller, S., and Tsurushita, N. (2006) An engineered human IgG1 antibody with longer serum half-life. J. Immunol. 176, 346-356
19. Petkova, S. B., Akilesh, S., Sproule, T. J., Christianson, G. J., Al Khabbaz, H., Brown, A. C., Presta, L. G., Meng, Y. G., and Roopenian, D. C. (2006) Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int. Immunol. 18, 1759-1769
20. Bertolotti-Ciarlet, A., Wang, W., Lownes, R., Pristatsky, P., Fang, Y., McKelvey, T., Li, Y., Li, Y., Drummond, J., Prueksaritanont, T., and Vlasak, J. (2009) Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. Mol. Immunol. 46, 1878-1882
21. Pan, H., Chen, K., Chu, L., Kinderman, F., Apostol, I., and Huang, G. (2009) Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn. Protein Sci. 18, 424-433
22. Wang, W., Vlasak, J., Li, Y., Pristatsky, P., Fang, Y., Pittman, T., Roman, J., Wang, Y., Prueksaritanont, T., and Ionescu, R. (2011) Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol. Immunol. 48, 860-866
23. Hvidt, A., and Linderstrom-Lang, K. (1954) Exchange of hydrogen atoms in insulin with deuterium atoms in aqueous solutions. Biochim. Biophys. Acta 14, 574-575
24. Hvidt, A., and Linderstrom-Lang, K. (1955) The kinetics of the deuterium exchange of insulin with D2O; an amendment. Biochim. Biophys. Acta 16, 168-169
25. Hvidt, A., and Nielsen, S. O. (1966) Hydrogen exchange in proteins. Adv. Protein Chem. 21, 287-386
26. Zhang, Z., and Smith, D. L. (1993) Determination of amide hydrogen exchange by mass spectrometry: a new tool for protein structure elucidation. Protein Sci. 2, 522-531
27. Engen, J. R. (2009) Analysis of protein conformation and dynamics by hydrogen/deuterium exchange MS. Anal. Chem. 81, 7870-7875
28. Skinner, J. J., Lim, W. K., Bedard, S., Black, B. E., and Englander, S. W. (2012) Protein hydrogen exchange: testing current models. Protein Sci. 21, 987-995
29. Skinner, J. J., Lim, W. K., Bedard, S., Black, B. E., and Englander, S. W. (2012) Protein dynamics viewed by hydrogen exchange. Protein Sci. 21, 996-1005
30. Zehl, M., Rand, K. D., Jensen, O. N., and Jørgensen, T. J. D. (2008) Electron transfer dissociation facilitates the measurement of deuterium incorporation into selectively labeled peptides with single residue resolution. J. Am. Chem. Soc. 130, 17453-17459
31. Rand, K. D., Zehl, M., Jensen, O. N., and Jørgensen, T. J. D. (2009) Protein hydrogen exchange measured at single-residue resolution by electron transfer dissociation mass spectrometry. Anal. Chem. 81, 5577-5584
32. Rand, K. D. (2013) Pinpointing changes in higher-order protein structure by hydrogen/deuterium exchange coupled to electron transfer dissociation mass spectrometry. Int. J. Mass Spectrom. 338, 2-10
33. Rand, K. D., Zehl, M., and Jorgensen, T. J. D. (2014) Measuring the hydrogen/deuterium exchange of proteins at high spatial resolution by mass spectrometry: overcoming gas-phase hydrogen/deuterium scrambling. Acc. Chem. Res. 47, 3018-3027
34. Schlothauer, T., Rueger, P., Stracke, J. O., Hertenberger, H., Fingas, F., Kling, L., Emrich, T., Drabner, G., Seeber, S., Auer, J., Koch, S., and Papadimitriou, A. (2013) Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. mAbs 5, 576-586
35. Sheff, J. G., Rey, M., and Schriemer, D. C. (2013) Peptide-column interactions and their influence on back exchange rates in hydrogen/deuterium exchange-MS. J. Am. Soc. Mass Spectrom. 24, 1006-1015
36. Trelle, M. B., Dupont, D. M., Madsen, J. B., Andreasen, P. A., and Jorgensen, T. J. (2014) Dissecting the effect of RNA aptamer binding on the dynamics of plasminogen activator inhibitor 1 using hydrogen/deuterium exchange mass spectrometry. ACS Cem. Biol. 9, 174-182
37. Rand, K. D., Pringle, S. D., Morris, M., Engen, J. R., and Brown, J. M. (2011) ETD in a traveling wave ion guide at tuned Z-spray ion source conditions allows for site-specific hydrogen/deuterium exchange measurements. J. Am. Soc. Mass Spectrom. 22, 1784-1793
38. Rand, K. D., Zehl, M., Jensen, O. N., and Jorgensen, T. J. (2010) Loss of ammonia during electron-transfer dissociation of deuterated peptides as an inherent gauge of gas-phase hydrogen scrambling. Anal. Chem. 82, 9755-9762
39. Stracke, J., Emrich, T., Rueger, P., Schlothauer, T., Kling, L., Knaupp, A., Hertenberger, H., Wolfert, A., Spick, C., Lau, W., Drabner, G., Reiff, U., Koll, H., and Papadimitriou, A. (2014) A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies. mAbs 6, 1229-1242
40. Houde, D., Arndt, J., Domeier, W., Berkowitz, S., and Engen, J. R. (2009) Characterization of IgG1 conformation and conformational dynamics by hydrogen/deuterium exchange mass spectrometry. Anal. Chem. 81, 5966
41. Iacob, R. E., Murphy, J. P., 3rd, and Engen, J. R. (2008) Ion mobility adds an additional dimension to mass spectrometric analysis of solution-phase hydrogen/deuterium exchange. Rapid Commun. Mass Spectrom. 22, 2898-2904
42. Shields, R. L, Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., Fox, J. A., and Presta, L. G. (2001) High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem. 276, 6591-6604
43. Bai, Y., Milne, J. S., Mayne, L., and Englander, S. W. (1993) Primary structure effects on peptide group hydrogen exchange. Proteins 17, 75-86
44. Good, D. M., Wirtala, M., McAlister, G. C., and Coon, J. J. (2007) Performance characteristics of electron transfer dissociation mass spectrometry. Mol. Cell. Proteomics 6, 1942-1951
45. Vaughn, D. E., Milburn, C. M., Penny, D. M., Martin, W. L., Johnson, J. L., and Bjorkman, P. J. (1997) Identification of critical IgG binding epitopes on the neonatal Fc receptor. J. Mol. Biol. 274, 597-607
46. Alsenaidy, M. A., Kim, J. H., Majumdar, R., Weis, D. D., Joshi, S. B., Tolbert, T. J., Middaugh, C. R., and Volkin, D. B. (2013) High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation. J. Pharm. Sci. 102, 3942-3956
47. Zheng, K., Yarmarkovich, M., Bantog, C., Bayer, R., and Patapoff, T. W. (2014) Influence of glycosylation pattern on the molecular properties of monoclonal antibodies. mAbs 6, 649-658
48. Houde, D., Peng, Y., Berkowitz, S. A., and Engen, J. R. (2010) Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol. Cell. Proteomics 9, 1716-1728
49. Guttman, M., Scian, M., and Lee, K. K. (2011) Tracking hydrogen/deuterium exchange at glycan sites in glycoproteins by mass spectrometry. Anal. Chem. 83, 7492-7499
50. Suzuki, T., Ishii-Watabe, A., Tada, M., Kobayashi, T., Kanayasu-Toyoda, T., Kawanishi, T., and Yamaguchi, T. (2010) Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J. Immunol. 184, 1968-1976
51. Wang, W., Lu, P., Fang, Y., Hamuro, L., Pittman, T., Carr, B., Hochman, J., and Prueksaritanont, T. (2011) Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab. Dispos. 39, 1469-1477
52. Inganas, M. (1981) Comparison of mechanisms of interaction between Protein-A from Staphylococcus aureus and human monoclonal IgG, IgA and IgM in relation to the classical Fc-gamma and the alternative F(ab')2-epsilon Protein - A interactions. Scand. J. Immunol. 13, 343-352
53. Potter, K. N., Li, Y. C., and Capra, J. D. (1996) Staphylococcal protein A simultaneously interacts with framework region 1, complementarity-determining region 2, and framework region 3 on human V(H)3-encoded Igs. J. Immunol. 157, 2982-2988
54. Ghose, S., Allen, M., Hubbard, B., Brooks, C., and Cramer, S. M. (2005) Antibody variable region interactions with Protein A: implications for the development of generic purification processes. Biotechnol. Bioeng. 92, 665-673
55. Zhu, Y., Hu, C., Lu, M., Liao, S., Marini, J. C., Yohrling, J., Yeilding, N., Davis, H. M., and Zhou, H. (2009) Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J. Clin. Pharmacol. 49, 162-175
56. Leabman, M. K., Meng, Y. G., Kelley, R. F., DeForge, L. E., Cowan, K. J., and Iyer, S. (2013) Effects of altered FcgammaR binding on antibody pharmacokinetics in cynomolgus monkeys. mAbs 5, 896-903
57. Schlessinger, J., Steinberg, I. Z., Givol, D., Hochman, J., and Pecht, I. (1975) Antigen-induced conformational changes in antibodies and their Fab fragments studied by circular polarization of fluorescence. Proc. Natl. Acad. Sci. U.S.A. 72, 2775-2779
58. Oda, M., Kozono, H., Morii, H., and Azuma, T. (2003) Evidence of allosteric conformational changes in the antibody constant region upon antigen binding. Int. Immunol. 15, 417-426
59. Burkitt, W., Domann, P., and O'Connor, G. (2010) Conformational changes in oxidatively stressed monoclonal antibodies studied by hydrogen exchange mass spectrometry. Protein Sci. 19, 826-835
60. Ferrant, J. L., Benjamin, C. D., Cutler, A. H., Kalled, S. L., Hsu, Y. M., Garber, E. A., Hess, D. M., Shapiro, R. I., Kenyon, N. S., Harlan, D. M., Kirk, A. D., Burkly, L. C., and Taylor, F. R. (2004) The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. Int. Immunol. 16, 1583-1594